本页面由Tiger Trade Technology Pte. Ltd.提供服务

Atea Pharmaceuticals, Inc.

3.16
+0.02000.64%
盘后3.15-0.0125-0.40%17:45 EST
成交量:31.72万
成交额:100.05万
市值:2.47亿
市盈率:-1.79
高:3.19
开:3.14
低:3.11
收:3.14
52周最高:4.02
52周最低:2.46
股本:7,812.68万
流通股本:6,000.97万
量比:1.02
换手率:0.53%
股息:- -
股息率:- -
每股收益(TTM):-1.7696
每股收益(LYR):-1.9983
净资产收益率:-37.98%
总资产收益率:-23.86%
市净率:0.78
市盈率(LYR):-1.58

数据加载中...

2024/02/02

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/02/02

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/02/02

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/02/02

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/02/02

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/11/28

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2023/11/09

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/11/09

重要事件披露

Form 8-K - Current report
2023/10/02

超过5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2023/08/09

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/08/08

重要事件披露

Form 8-K - Current report
2023/06/22

重要事件披露

Form 8-K - Current report
2023/05/22

超过5%披露

Form SC 13D - General statement of acquisition of beneficial ownership
2023/05/08

重要事件披露

8-K - Current report
2023/05/08

季度报告

10-Q - Quarterly report [Sections 13 or 15(d)]
2023/02/28

重要事件披露

8-K - Current report
2023/02/28

年度报告

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2023/02/10

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2023/02/10

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2023/02/09

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals